Cilta-Cel Outcomes in R/R Multiple Myeloma: Omar Castaneda Puglianini, MD

Video

The hematology and medical oncologist at Moffitt Cancer Center discussed results from the phase 1b/2 CARTITUDE-1 trial of cita-cel in R/R MM.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Omar Castaneda Puglianini, MD, hematology and medical oncologist, Moffitt Cancer Center, to learn more about findings from the phase 1b/2 CARTITUDE-1 trial (NCT03548207) evaluating ciltacabtagene autoleucel (cilta-cel) in patients with relapsed/refractory multiple myeloma.

Investigators found that the overall response rate (ORR) was 97.9%. With longer follow-up, responses to the CAR T-cell therapy deepened. Castaneda Puglianini noted that the stringent complete response (sCR) rate increased from 67% at a median follow-up of 8 to 9 months, to 80.4% at 18 months.

The median duration of response with the agent was 21.8 months, and the median progression-free survival (PFS) was 22.8 months, Castaneda Puglianini adds. Notably, for patients who achieved a sCR, the median PFS was not reached. Response rates were also comparable across patient subgroups, including those who received previous lines of therapy and extramedullary disease. Overall, the efficacy demonstrated by cilta-cel on this study was impressive, Castaneda Puglianini concludes.

Related Videos
Paula Cannon, PhD, the president elect of ASGCT and a distinguished professor of microbiology at Keck School of Medicine of USC
George Tachas, PhD
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
© 2024 MJH Life Sciences

All rights reserved.